NY Dementia Caregiver Guide: Programs, Legal Planning, Respite (2026)

If someone you love has been diagnosed with dementia, or you suspect they should be, you are one of roughly 776,000 New Yorkers shouldering this work in 2026. The good news is that New York has built more public infrastructure around dementia care than almost any other state. The bad news is that the infrastructure is invisible until somebody walks you through it. That's what this guide does.

This is the dementia-specific deep dive in our New York caregiver pillar. For the broader landscape, paid family caregiving in NY, time off work, all nine respite funding streams, see our Caregiver pillar landing page, How to Get Paid as a Family Caregiver in New York, and Respite Care in New York. This article focuses on what changes when the diagnosis is dementia.

The 90-Second Version

If you read nothing else, read these eleven things.

1. Call the Alzheimer's Association 24/7 helpline at 1-800-272-3900. It is free, in 200+ languages, staffed by clinically trained care consultants, and is the single best front door to NY's dementia infrastructure. A care consultant will tell you which Center of Excellence for Alzheimer's Disease (CEAD), which Area Agency on Aging caregiver coordinator, and which Alzheimer's Association NY chapter to call next.
2. 426,500 New Yorkers age 65+ are living with Alzheimer's disease in 2026. Roughly 776,000 unpaid caregivers in NY are providing dementia care this year. Statewide Alzheimer's deaths totaled approximately 3,204 (mortality rate 16.1 per 100,000). Alzheimer's Association 2026 Facts and Figures, NY state pages.
3. NY has 10 Centers of Excellence for Alzheimer's Disease (CEADs). NYU Langone, Columbia, SUNY Downstate, Montefiore, Stony Brook, Albany Med, Glens Falls, SUNY Upstate, University of Rochester, and University at Buffalo. Each CEAD provides comprehensive diagnostic evaluation, biomarker workup, anti-amyloid infusion access, and family education, funded by NYSDOH at roughly $2.0–$2.35 million per CEAD per multi-year cycle.
4. Get the Health Care Proxy and Durable Power of Attorney signed now. New York Public Health Law Article 29-C is explicit that dementia is not mental illness for proxy purposes, a person with mild-to-moderate dementia can still validly sign a Health Care Proxy if they understand the act. The legal window closes earlier than families think.
5. Two disease-modifying drugs are now FDA-approved and covered. Lecanemab (Leqembi) and donanemab (Kisunla) slow Alzheimer's clinical progression by 22–35% over 18 months in early symptomatic AD with confirmed amyloid pathology. Medicare Part B covers them via the ALZ-NET registry pathway; NY Medicaid (NYRx) covers them with prior authorization (PDL revised April 23, 2026). They are not a cure.
6. Medicare's GUIDE Model launched July 1, 2024 and includes up to $2,500/year of caregiver respite. Sixteen NY organizations are GUIDE participants, Mount Sinai, Northwell, Columbia Neurology, ArchCare Dementia Care Connect, Isaac Health, Tembo Health, RBA Behavioral Wellness, CareND Neurology Group, and others. If your loved one has traditional Medicare and a confirmed dementia diagnosis, ask your CEAD or PCP whether your nearest GUIDE participant can enroll them.
7. Medicare does NOT cover long-term nursing home dementia care. Medicare pays for up to 100 days of post-hospitalization skilled nursing only. Medicaid is the only realistic public payer for custodial nursing home care, after a spend-down. NY enforces a 60-month look-back for institutional Medicaid; community Medicaid currently has no look-back (the long-anticipated 30-month community look-back was delayed again in the FY 2026 enacted budget).
8. NY caregiver respite is layered, at least nine streams. Dementia families have access to all nine streams in our Respite Care in New York guide, plus the GUIDE Model $2,500/year benefit. The Alzheimer's Association 24/7 helpline (1-800-272-3900) is the fastest way to learn which streams you qualify for.
9. MOLST is for late-stage dementia, not early. The pink-paper Medical Orders for Life-Sustaining Treatment (DOH-5003) is a current medical order, not an advance directive. Use it when the patient is in long-term care, at FAST stage 6c–7, and the family has had a goals-of-care conversation with the attending physician. Premature MOLST execution can cause under-treatment of reversible conditions.
10. NY does not require physicians to report cognitive impairment to the DMV. A primary care doctor or memory specialist can voluntarily file DMV form DS-7, meaning you don't have to be the one to take the keys. The 2024 JAMA Network Open analysis found mandatory-reporting states have higher dementia underdiagnosis because patients avoid the doctor.
11. Hospice is appropriate when dementia reaches FAST 7c with a complication. CMS Local Coverage Determination L34567 sets the eligibility floor: FAST stage 7 plus at least one secondary condition (aspiration pneumonia, septicemia, stage 3–4 pressure ulcers, weight loss ≥10% in 6 months, or albumin <2.5 g/dL). Hospice is not giving up, it is the most concentrated dose of caregiving support the U.S. healthcare system offers a dying patient.

How This Guide Is Organized

The article walks through the eight central questions every NY dementia family eventually asks, in roughly the order they ask them.

1. The Size and Shape of Dementia Caregiving in New York

1.1 The headline numbers

The Alzheimer's Association's 2026 Alzheimer's Disease Facts and Figures, published in Alzheimer's & Dementia (doi:10.1002/alz.71345), is the annually-refreshed primary source on NY dementia epidemiology.

• NY adults 65+ living with Alzheimer's disease (2026): 426,500.
• NY unpaid family caregivers of someone with Alzheimer's or other dementia: approximately 776,000.
• Statewide Alzheimer's deaths (most recent year reported): 3,204.
• Statewide Alzheimer's mortality rate: 16.1 per 100,000 population.
• United States adults 65+ living with Alzheimer's in 2026: 7.4 million, about 1 in 9 people 65+. NY accounts for roughly 5.8% of that national prevalence.
• United States 2025 unpaid hours of dementia care: more than 19 billion hours, valued at over $446 billion at replacement-wage rates. Pro-rated by NY's caregiver population, NY's share is roughly 800–900 million hours annually, valued at roughly $19–21 billion.

1.2 The race and ethnicity overlay

The 2026 Facts and Figures race/ethnicity findings have direct relevance to NY, where Black and Hispanic/Latino populations together comprise roughly 34% of the state's population.

• Older Black Americans are about 2× as likely as older White Americans to have Alzheimer's or other dementia. Roughly 19% of Black adults 65+ have Alzheimer's, vs. 10% of White adults 65+.
• Older Hispanic/Latino Americans are about 1.5× as likely as White peers, roughly 14% of Hispanic adults 65+.
• Modifiable risk factors account for a larger share of cases in non-White populations: 33% in Latinos, 28% in African Americans, 22% in Whites. Hypertension, diabetes, obesity, sleep apnea, midlife hearing loss, and social isolation are the top contributors (Lancet Commission on Dementia 2024 update).
• Despite higher prevalence, Black and Hispanic adults 65+ are less likely to be formally diagnosed with dementia. Diagnosis disparity is driven by access barriers (specialist scarcity, language, transportation), implicit bias in primary care, and lower trust in research/health-care institutions stemming from historical inequities.

This means the NY dementia caregiving population is disproportionately Black and Latina women, often working-age, often sandwich-generation, often without paid leave, often relying on patchwork arrangements rather than formal long-term services and supports.

1.3 The sandwich-generation overlay

The 2025 AARP/National Alliance for Caregiving Caregiving in the US 2025 survey reports that 29% of all family caregivers are sandwich-generation (simultaneously caring for an adult and a child under 18), rising to 47% among caregivers under age 50. With 776,000 NY dementia caregivers, that implies roughly 225,000–235,000 NY sandwich-generation dementia caregivers in 2026.

1.4 The geographic distribution inside NY

NY's dementia caregiving load is not evenly distributed:

• NYC five boroughs: roughly 45% of NY's dementia patient population; concentrated in older immigrant communities (especially Queens and Brooklyn) where adult-children-caregivers face language and benefits-navigation barriers.
• Long Island (Nassau + Suffolk): roughly 14%; affluent on average, high private-pay capacity.
• Hudson Valley + Capital Region: roughly 13%; mix of suburban and rural.
• Western NY (Buffalo + Niagara): roughly 9%; older population skew, more economic stress.
• Finger Lakes + Central NY + North Country + Southern Tier: roughly 19%; rural caregiving challenges, distance to CEADs, scarce in-home aides.

2. Where to Go for a Real Diagnosis

The single most important early decision a NY dementia family makes is where to get evaluated. A 30-minute primary care visit is not a dementia evaluation. A real workup involves cognitive testing, neuroimaging, biomarker analysis, medication reconciliation, a functional assessment, and a written care plan. Three pathways:

2.1 The Annual Wellness Visit cognitive screen, Medicare Part B

Original Medicare and Medicare Advantage both must include cognitive impairment screening as a structured element of the Annual Wellness Visit (HCPCS code G0438 for the initial AWV, G0439 for subsequent annual AWVs). Common tools: Mini-Cog, GPCOG, MIS (Memory Impairment Screen). If the screen flags concerns, the clinician should proceed to a deeper Cognitive Assessment & Care Plan, see 2.2.

Note on codes: G0444 is the Annual Depression Screening code, not the cognitive assessment code. CMS retired HCPCS G0505 on January 1, 2018; the current code for the deeper cognitive assessment is CPT 99483. Some older marketing materials still cite G0505, that code is dead.

2.2 Cognitive Assessment and Care Plan Services, CPT 99483

CPT 99483 is a Medicare Part B benefit, billable in addition to E/M when documentation requirements are met. It is a roughly 50-minute visit conducted by an MD/DO/NP/PA/clinical nurse specialist that produces a written care plan shared with the patient and caregiver.

Required elements per the CMS Cognitive Assessment & Care Plan Services page: cognitive examination; review of medical/surgical/family/social history; functional assessment of basic and instrumental ADLs (using validated instruments such as FAST or CDR); medication reconciliation focused on high-risk drugs (anticholinergics, benzodiazepines); decisional capacity evaluation; staff/caregiver knowledge assessment; safety evaluation (driving, home, financial); identification of caregiver needs; referrals; advance care planning; written care plan.

Most NY families never hear about CPT 99483 because primary care offices don't always offer it. Ask. The CEADs offer it routinely.

2.3 The CEADs (Centers of Excellence for Alzheimer's Disease)

The 10 NYSDOH-designated CEADs as of 2026 are:

CEADs offer comprehensive diagnostic evaluation (neuropsychological testing, neuroimaging, biomarker workup), care planning and family support, specialty consultation to PCPs across the state, anti-amyloid infusion programs (lecanemab/donanemab), caregiver education classes, and clinical research recruitment. State funding has been roughly $2.0–$2.35 million per CEAD per multi-year cycle (e.g., SUNY Downstate's 2022 $2.3M renewal, Stony Brook's 2022 $2.35M award).

2.4 The NIH Alzheimer's Disease Research Centers (ADRCs)

NIA-funded ADRCs are clinical/translational research centers, separate from NY's state CEADs, though they often co-locate. NY hosts:

• NYU Langone ADRC (Silberstein Alzheimer's Institute / Pearl I. Barlow Center), one of the oldest and largest in the U.S.
• Mount Sinai ADRC, directed by Mary Sano, PhD.
• Columbia/Taub Institute ADRC.
• Albert Einstein ADRC (affiliated with Montefiore).
• University of Rochester ADRC.

ADRCs are the right place to enroll in clinical trials (e.g., next-generation anti-amyloid therapies, anti-tau therapies, prevention trials in pre-symptomatic mutation carriers).

2.5 What "memory mimics" must be ruled out

A real workup distinguishes Alzheimer's from other causes, and several of those other causes are treatable or reversible. Reversible/treatable mimics that any competent dementia evaluation rules out:

• B12 deficiency
• Hypothyroidism
• Normal pressure hydrocephalus
• Major depression (pseudo-dementia)
• Polypharmacy / anticholinergic burden / benzodiazepine misuse
• Urinary tract infection-induced delirium
• Subdural hematoma
• Sleep apnea
• Heavy alcohol use

If the primary care office didn't draw labs (TSH, B12, CBC, CMP, sometimes RPR/HIV), didn't order a brain MRI, and didn't reconcile medications, you didn't have a real workup, go to a CEAD.

3. The Unique NY Dementia Infrastructure

This is where NY's story diverges from a Texas or Florida or Mississippi article. NY has built a five-pillar public-health-meets-clinical-care infrastructure for dementia that no other state has assembled in the same density.

3.1 NYSDOH Bureau of Healthy Aging, the public-health backbone

The Bureau of Healthy Aging within NYSDOH's Office of Public Health is the state's dementia public-health hub, with three core program lines: the CEADs (clinical-care arm); the Alzheimer's Disease Caregiver Support Initiative (community-services arm); and the CDC BOLD Cooperative Agreement (epidemiology and surveillance arm).

3.2 Alzheimer's Disease Caregiver Support Initiative (ADCSI)

ADCSI is the state's flagship caregiver-support funding stream, administered by NYSDOH's Bureau of Healthy Aging.

• Funding level: approximately $26 million annually.
• Structure: Single Source Procurement to 10 grantees statewide, plus a contract with the Coalition of New York State Alzheimer's Association Chapters that flows funding to all 7 NY chapters for the 24/7 helpline, support groups, care consultations, education, and outreach.
• Services delivered: care consultations, evidence-based caregiver training (Savvy Caregiver, REACH-II, Habilitation Therapy), the 24/7 helpline 1-800-272-3900 (200+ languages via interpreter), support groups, public outreach, professional caregiver training.
• Underserved Communities track: RFA history shows a separate procurement targeting underserved communities, rural North Country, Southern Tier; immigrant communities in Queens/Brooklyn; African-American communities across NYC; Latino communities in the Bronx and Western Queens.
• Geographic reach: ADCSI claims service reach across all 62 counties.

If you are a NY caregiver and you don't know where to start, the simplest action you can take today is to call 1-800-272-3900. It's free, 24/7, in your language, and a care consultant will tell you which CEAD, which AAA, which ADCSI grantee is right for you.

3.3 The Alzheimer's Association, 7 NY chapters

The Coalition of New York State Alzheimer's Association Chapters delivers ADCSI-funded community services through 7 chapters covering all 62 counties:

All chapters share the 24/7 Helpline 1-800-272-3900, the MedicAlert + Safe Return wandering registry, family-led support groups, evidence-based caregiver education programs (Savvy Caregiver, Powerful Tools for Caregivers, Memory Sundays), Memory Cafés, and Walk to End Alzheimer's events.

3.4 NYU BOLD Public Health Center of Excellence

NYU Grossman School of Medicine is one of three CDC-designated BOLD (Building Our Largest Dementia Infrastructure) Public Health Centers of Excellence for early dementia detection. The Center develops a 4-step early detection care pathway and provides technical assistance to states. NYU's BOLD PHCOE is housed in the Division of Geriatric Medicine and Palliative Care (Pearl I. Barlow Center).

NY State separately holds a CDC BOLD Cooperative Agreement (NU58DP006911) awarded September 30, 2023 for a 5-year period (FY 2024–FY 2028). Activities: brain-health awareness; chronic-disease comorbidity management for dementia; partnerships to improve early detection and diagnosis; surveillance via the BRFSS Cognitive Decline and Caregiver modules.

3.5 GUIDE Model (Guiding an Improved Dementia Experience), CMS

CMS launched the GUIDE Model on July 1, 2024, an 8-year alternative payment model for comprehensive dementia care, running through June 30, 2032.

• Per-Beneficiary Per-Month (PBPM) payment to the GUIDE participant for comprehensive dementia care, care navigator, 24/7 helpline, caregiver education, behavioral support.
• Up to $2,500 per year of caregiver respite for qualifying traditional-Medicare beneficiaries with confirmed dementia diagnosis.
• Established Track participants began delivering services 7/1/2024; New Track participants began delivering services 7/1/2025.

Sixteen NY organizations are GUIDE participants. Confirmed participants include Mount Sinai Health System (New Track, services since 7/1/2025), Northwell Health, Columbia University Department of Neurology, ArchCare Dementia Care Connect, Isaac Health, Tembo Health, RBA Behavioral Wellness, and CareND Neurology Group, with additional NY participants confirmed via LeadingAge NY's GUIDE tracker and the CMS GUIDE participant list.

If your loved one has traditional Medicare and a confirmed dementia diagnosis, ask your PCP or CEAD whether the nearest GUIDE participant can enroll them. The $2,500/year of respite is a new and underutilized benefit.

4. Real Treatments, The 2026 Disease-Modifying Therapy Landscape

The 2010s and early 2020s era when "there is nothing you can do" was nearly true is over.

4.1 Lecanemab (Leqembi) and donanemab (Kisunla)

Two FDA-approved disease-modifying anti-amyloid therapies are now available at every NY CEAD.

Required to qualify (both drugs): confirmed amyloid pathology (amyloid PET or CSF Aβ42/40 ratio), MCI or mild dementia stage (moderate or severe AD = denial), APOE genotyping for ARIA risk stratification, baseline MRI within 12 months pre-initiation, and serial MRIs to monitor for ARIA-E (edema) and ARIA-H (microhemorrhages).

Coverage:

• Medicare Part B covers both via the National Coverage Determination NCD 200.3 framework, contingent on enrollment in a CMS-approved registry (the Alzheimer's Network for Treatment and Diagnostics, ALZ-NET).
• NY Medicaid (NYRx) covers both with prior authorization, per the NYRx PDL revised April 23, 2026. PA criteria mirror FDA labeling (confirmed amyloid pathology, MCI or mild dementia stage, APOE genotyping, baseline MRI). No step therapy is imposed as of the April 2026 PDL update. PA submitted via CoverMyMeds (electronic) or fax to (800) 268-2990; clinical call center (877) 309-9493. The infusion administration itself is billed under the medical benefit at the infusion clinic (typically a CEAD).
• Out-of-pocket on Medicare: with a Medigap plan, OOP can be near zero. Without Medigap, 20% Part B coinsurance (~$5,300/year on Leqembi list price) plus the Part B deductible.

These drugs are not a cure. They slow clinical progression by roughly 22–35% over 18 months in early symptomatic AD. They do not work in moderate or severe AD. The clinical question with every patient is: is the amyloid pathology confirmed, is the staging mild, and is the patient/family prepared for monthly or bimonthly infusions plus serial MRI monitoring?

4.2 Brexpiprazole (Rexulti) for AD-associated agitation

The FDA approved brexpiprazole for Alzheimer's-associated agitation on May 10, 2023, the first non-off-label antipsychotic indicated for behavioral symptoms of dementia. It is on the NYRx PDL with PA requiring documentation of agitation interfering with care and failure of behavioral interventions. Not a routine first-line agent. Behavioral interventions, environmental adjustments, and treatment of treatable triggers (pain, infection, constipation) come first.

4.3 Cognitive enhancers, donepezil, rivastigmine, galantamine, memantine

The cholinesterase inhibitors (donepezil/Aricept, rivastigmine/Exelon, galantamine/Razadyne) and the NMDA receptor antagonist memantine (Namenda) remain on every dementia treatment ladder. They produce modest symptomatic benefit, typically a 6–12 month delay in clinical decline. Side-effect profile (GI for cholinesterase inhibitors; sedation and dizziness for memantine) often determines tolerability. NYRx covers all four generically without PA.

5. Get the Legal Documents Done, Now

The single most important financial and legal conversation a NY dementia family will have is with a NY-licensed elder-law attorney, while the person with dementia still has capacity. The legal window closes earlier than families think.

5.1 Health Care Proxy, Public Health Law Article 29-C

Statute: NY Public Health Law §§ 2980–2994. Primary appointment provision at § 2981.

• A "competent adult" may execute a Health Care Proxy. Every adult is presumed competent unless a court has adjudicated otherwise.
• Critically, "mental illness" under § 2982 explicitly excludes dementia, including Alzheimer's disease. This was the basis for the holding in Matter of Mildred M.J., 43 A.D.3d 1391 (4th Dept. 2007), where the Fourth Department upheld a proxy executed by a woman with moderate dementia.
• Capacity standard: "the ability to understand and appreciate the nature and consequences of health care decisions, including the benefits and risks of and alternatives to any proposed health care."
• A proxy takes effect when the attending physician (and a concurring physician for life-sustaining-treatment decisions) determines the principal lacks capacity.
• The proxy form does not need to be notarized, but it must be signed by two adult witnesses (the agent cannot be a witness).

The article-level guidance: execute a Health Care Proxy as soon as a memory concern is raised, not after the diagnosis hardens.

5.2 Family Health Care Decisions Act, Public Health Law Article 29-CC

If the patient never executed a proxy and lacks capacity, NY PHL §§ 2994-a through 2994-u (the Family Health Care Decisions Act, enacted 2010) creates a surrogate decision-making hierarchy:

1. Court-appointed Article 81 guardian with health-care decision authority.
2. Spouse or domestic partner.
3. Adult child (18+).
4. Parent.
5. Adult sibling (18+).
6. "Close friend", an 18+ adult who has maintained regular contact and signs a § 2994-d statement.

The FHCDA covers hospitals, nursing homes, and (since 2015) hospice settings, but it does not apply in private homes. So a family caring for someone at home, without a Proxy, has no statutory decision-making authority under FHCDA. This is one more reason to execute a Proxy now.

5.3 Durable Power of Attorney, General Obligations Law § 5-1501

Statute: NY GOL §§ 5-1501 through 5-1514. The 2021 reform (L. 2020, ch. 323) amended §§ 5-1501 through 5-1514 effective June 13, 2021 for all POAs signed on or after that date.

Key 2021 reform changes relevant to dementia families:

• Eliminated the separate Statutory Gifts Rider; gifts are now incorporated into the Modifications section (with a $5,000/year non-rider limit; higher gifts require explicit modification authority).
• "Substantially compliant" language allowed, exact wording no longer required.
• "Safe harbor" for third parties (banks, financial institutions) accepting an acknowledged POA in good faith.
• Sanctions authorized against a third party that "unreasonably refuses" a valid POA.
• Two disinterested witnesses required (one may also be the notary public).
• A POA is durable unless it expressly says otherwise, meaning it survives the principal's later incapacity, which is the entire point for dementia families.

Every dementia family should have both a Health Care Proxy and a durable POA. The Proxy covers medical decisions; the POA covers financial decisions, real estate, taxes, and government benefits applications, including Medicaid. Note: NY's Medicaid application can be filed by a POA agent only if the POA explicitly grants "Government Benefits" authority.

5.4 MOLST (Medical Orders for Life-Sustaining Treatment, DOH-5003)

MOLST is not an advance directive. It is a physician (or NP/PA) signed medical order, on a bright-pink form, that travels with the patient across care settings.

• Use case: seriously ill patients, including advanced dementia, likely to face a foreseeable medical emergency within the next year, where the patient/surrogate has stated preferences about CPR, intubation, hospital transfer, artificial nutrition, antibiotics, and dialysis.
• MOLST is the only NY-authorized form for nonhospital DNR and DNI orders.
• Must be signed by the patient (if capacity) or surrogate (FHCDA hierarchy or Health Care Proxy), and discussed in a goals-of-care conversation with the physician/NP/PA.
• MOLST is portable, emergency responders and ER staff are required to honor it.

The most important nuance: MOLST is for late-stage dementia in a long-term-care setting. Early- or mild-stage families should focus on Proxy + POA + goals-of-care conversations, and execute MOLST when (a) the patient is in long-term care, (b) is at FAST 6c–7, and (c) the family has had a goals-of-care conversation with the attending. Premature MOLST execution can lead to under-treatment of reversible conditions (e.g., a UTI not aggressively treated because the MOLST limits antibiotics).

5.5 Article 81 Guardianship, Mental Hygiene Law § 81

When a person has dementia and never executed a Proxy or POA, and the family needs decision-making authority, the path is MHL Article 81 guardianship of person and/or property.

• Filed in NY State Supreme Court.
• Functional standard, not diagnostic standard: incapacity is shown when the person is unable to provide for personal needs and/or property and cannot understand the consequences of that inability, established by clear and convincing evidence.
• Least restrictive alternative principle: the court tailors the guardian's powers to the specific needs (limited guardianship). A dementia patient with mild impairment may need only a property guardian, not a personal-needs guardian.
• Hearing typically held within 28 days of petition filing.
• Court appoints a court evaluator to investigate; the alleged incapacitated person (AIP) has counsel.
• Cost: typically $4,000–$15,000 in attorney + court evaluator fees, paid out of the AIP's estate; can be more in contested cases.

Article 81 should be the last legal tool, not the first. Encourage Proxy + POA in early dementia. Article 81 becomes necessary when (a) no advance documents exist, (b) family disputes are blocking decision-making, (c) the patient is being financially exploited and a court order is needed, or (d) a third party is refusing to honor a POA.

5.6 The Medical Aid in Dying Act, not a dementia advance directive

Governor Hochul signed the Medical Aid in Dying Act on February 6, 2026, effective August 5, 2026. The Act is not a dementia advance-directive law. It requires the patient to have decision-making capacity at the time of the request, which excludes most dementia patients past mild stage. Many families will incorrectly assume MAID applies to dementia. It does not.

For NY families seeking a non-statutory expression of late-stage dementia preferences, advocacy organizations (End of Life Choices NY, dementia-directive.org) circulate template "Dementia Directives" that can be attached to a Health Care Proxy as guidance for the agent. These are not statutorily binding the way the Proxy itself is, but a thoughtful agent will follow them.

6. Who Pays for What: Medicare, Medicaid, GUIDE, NYRx

6.1 Medicare's coverage limits, what Medicare does and does not cover

6.2 NY Medicaid, the dominant funder of long-term dementia care

Three pathways:

(a) Institutional Medicaid for long-term nursing home care

• Income limit (2025, indexed for 2026): roughly $1,800/month NAMI (net available monthly income) goes to the facility; spousal impoverishment minimum allowance applies for the community spouse.
• Resource limit: $32,396 individual / $43,781 couple (2025; 2026 figures pending NYSDOH GIS update).
• 60-month look-back for institutional Medicaid; community Medicaid currently has no look-back (the long-anticipated 30-month community look-back was again delayed in the FY 2026 enacted budget).
• Average NY private-pay nursing home rate: $15,000–$20,000/month in NYC metro, $12,000–$15,000/month upstate.

(b) MLTC (Managed Long Term Care) for community dementia care

• The NY default for community-based long-term services and supports for dual-eligibles 18+ with a 120-day-or-more LTSS need.
• Eligibility floor: Nursing Facility Level of Care via the Community Health Assessment administered by the NY Independent Assessor (NYIA) under the MRT 1115 redesign framework. Cognitive impairment alone does not auto-qualify, but an assessment score reflecting moderate-to-severe cognitive impairment + ADL needs (typically supervision in 2+ ADLs, IADL impairments, or behavioral risk) usually qualifies.
• MLTC plans authorize: home health aide hours (up to 24/7 in some cases), personal care, social adult day services (SADS, distinct from medical model adult day), nutritional supports, durable medical equipment, transportation to medical appointments.
• "Behavioral health track" in MLTC: MAP-HARP (Medicaid Advantage Plus paired with Health and Recovery Plan) integrates behavioral health home and community services with LTSS for individuals meeting both BH and LTSS criteria. For dementia patients with severe BPSD plus a primary serious mental illness diagnosis meeting HARP eligibility, MAP-HARP can layer in psychiatric rehabilitation, peer support, and crisis services. (Without a primary SMI diagnosis, dementia + BPSD typically does not qualify for HARP.)

(c) NHTD (Nursing Home Transition and Diversion) 1915(c) Waiver

• For Medicaid-eligible adults 18+ requiring NF level of care who choose to receive services in the community.
• 2026 status: Enrollment cap of 9,400 finalized for waiver years 2025-26 / 2026-27 / 2027-28 (CMS amendment NY.0444 approved November 23, 2025). Proportional regional intake when slots open. New referrals are currently constrained, many NY caregivers will find that other pathways (MLTC, NFCSP, EISEP) are more accessible in 2026.
• Persons with dementia can be NHTD participants if they have a designated representative for service planning.
• Services include: Service Coordination, Community Transitional Services, Home and Community Support Services (HCSS), Independent Living Skills Training, Community Integration Counseling, Environmental Modifications, Assistive Technology, Respiratory Therapy, Nutritional/Dietary Counseling, Moving Assistance.

NHTD is not a dementia waiver. Some online resources frame it that way; that is misleading. NHTD is a Nursing Home Transition and Diversion 1915(c) waiver with cognitive impairment as one qualifying functional criterion among many. NY does not have a standalone dementia waiver.

6.3 NYRx, disease-modifying therapy coverage

NYRx (the NY Medicaid Pharmacy Program, administered through Magellan/Gainwell with Preferred Drug Program oversight by NYSDOH) covers FDA-approved anti-Alzheimer therapies subject to prior authorization. The NYRx PDL revised April 23, 2026 lists both lecanemab and donanemab as covered with PA. PA criteria mirror FDA labeling (confirmed amyloid pathology, MCI or mild dementia, APOE genotype, baseline MRI). No step therapy is imposed as of the April 2026 PDL update.

6.4 GUIDE Model, the new federal pillar

(Discussed in detail in Section 3.5.) Per-Beneficiary Per-Month payment to the GUIDE participant for comprehensive dementia care, plus up to $2,500 per year of caregiver respite for traditional-Medicare GUIDE-enrolled dementia patients. Sixteen NY participants. If your loved one has traditional Medicare, ask.

7. Behaviors and Care Techniques

Behavioral and Psychological Symptoms of Dementia (BPSD), agitation, aggression, psychosis, depression, sundowning, sleep disturbance, affect 80–97% of dementia patients at some point. The first principle of NY dementia care is behavioral interventions before drugs. NY families have access to several evidence-based techniques.

7.1 Validation Therapy (Naomi Feil)

Developed by Naomi Feil, MSW, between 1963 and 1980. A person-centered communication method classified into four stages: Malorientation, Time Confusion, Repetitive Motion, Vegetation. Core techniques: linking behavior to unmet needs; matching emotion; centering; rephrasing; using touch and music. Evidence base from Cochrane Reviews (Neal & Barton Wright, 2003; Scales et al., 2018) shows reductions in agitation, increased communication, and reduced psychotropic medication use.

The Validation Training Institute (vfvalidation.org) certifies workers and group leaders. Several NY Alzheimer's Association chapters offer Validation-informed family caregiver training.

7.2 Reminiscence Therapy

Structured engagement with a person's life history through photos, music, scents, objects, life-story books. Cochrane Review (Woods et al., 2018): modest improvements in mood and quality of life, with possible cognitive benefits. Frequently incorporated into adult day programs, memory cafés, and Alzheimer's Association support groups across NY.

7.3 Music & Memory

National program (musicandmemory.org) that creates personalized music playlists for individuals with dementia, delivered via headphones. NYC Health + Hospitals has deployed Music & Memory across multiple skilled nursing facilities (Coler, Sea View, Henry J. Carter), with reductions in antipsychotic use and improved quality-of-life metrics. Outside NYC, individual nursing homes and SADS programs have adopted Music & Memory often with NYSOFA or private foundation seed funding.

7.4 Person-Centered Care, Eden Alternative + Green House Project

The Eden Alternative (edenalt.org) was founded by William H. Thomas, MD, in 1991 while he was medical director of Chase Memorial Nursing Home in New Berlin, NY. The Eden 10 Principles aim to eliminate loneliness, helplessness, and boredom. The Green House Project (thegreenhouseproject.org) was founded by Thomas in 2003 as a built-environment expression of Eden principles: small homes (10–12 elders), private rooms, open kitchen, integrated living. Green House homes are deemed-equivalent skilled nursing facilities for Medicare/Medicaid certification. St. John's Home in Rochester is a long-running Green House Project NY site.

7.5 Habilitation Therapy (Paul Raia, PhD)

Developed by Paul Raia, PhD, formerly VP of Clinical Services at the Alzheimer's Association MA/NH chapter. A 13-hour person-centered care curriculum that trains caregivers to approach BPSD by identifying the underlying unmet need or environmental trigger and adapting the environment/communication rather than confronting the behavior. The Alzheimer's Association offers a 7-hour train-the-trainer program for professional providers across NY; some NY chapters incorporate Habilitation-informed teaching into family caregiver education.

7.6 Behavioral interventions for specific symptoms

7.7 Caregiver-focused evidence-based programs

Several evidence-based caregiver-skills-training programs are offered through NY ADCSI grantees and Alzheimer's Association NY chapters:

• REACH-II (Resources for Enhancing Alzheimer's Caregiver Health), multi-component skills training; reduces caregiver depression and burden (Schulz et al., Ann Intern Med 2006).
• Savvy Caregiver, 6-session program.
• Powerful Tools for Caregivers, 6-session self-care program offered widely through NYSOFA AAA Caregiver Resource Centers.
• STAR-C (STAR Caregivers), behavioral intervention training.
• Tailored Activity Program (TAP), OT-led individualized engagement program.

Ask the Alzheimer's Association 24/7 helpline (1-800-272-3900) or your CEAD which programs run in your county.

8. Respite Options for NY Dementia Caregivers

NY's nine respite funding streams are detailed in our Respite Care in New York deep guide. The dementia-specific layers worth highlighting:

1. NFCSP / Title III-E, the National Family Caregiver Support Program statutorily covers caregivers of any-age individuals with Alzheimer's disease or related disorders (in addition to caregivers of individuals 60+). 42 USC § 3030s. One of the few federal benefits that drops the age floor for ADRD caregivers.
2. NYSOFA State Respite Program, 6 community organizations covering 23 counties. Many of these grantees prioritize dementia caregivers in their intake. Catholic Charities Albany covers 14 counties; EAC Inc covers Nassau; Nascentia covers Onondaga; Madison County OFA covers Madison; NY Foundation for Senior Citizens covers all 5 NYC boroughs; RiseWell Community Services covers Suffolk.
3. ADCSI grantees, most ADCSI grantees in NY operate caregiver respite vouchers as a service component, often $300–$600 per caregiver per year.
4. MLTC supplemental respite, many MLTC plans authorize respite hours (up to 14 days/year inpatient or community respite, plan-specific) for plan members.
5. Medicare hospice 5-day inpatient respite, once the patient is on hospice, the family qualifies for a 5-day inpatient respite per benefit period at a Medicare-certified hospice facility. 42 CFR § 418.108. Reusable per benefit period.
6. VA PCAFC respite, for veterans with dementia service-connected at 70%+ where the veteran needs personal-care assistance with activities of daily living, the VA Program of Comprehensive Assistance for Family Caregivers (PCAFC) includes ≥30 days/year respite for the primary family caregiver. 38 USC § 1720G.
7. GUIDE Model respite benefit, up to $2,500/year of respite for traditional-Medicare beneficiaries enrolled with a NY GUIDE participant. The newest dementia-specific respite stream, launched July 1, 2024.
8. Alzheimer's Association NY chapter respite vouchers, Western NY chapter and others operate respite voucher pilots; eligibility and dollar amount vary.
9. NYSCRC Lifespan voucher, Lifespan of Greater Rochester's NYSCRC program offers up to $600 per first-time approved caregiver applicant (NOT the older $500 figure that still circulates). Voucher can pay an agency, individual contractor, or hired family member or friend, one of the few NY pathways that can pay a friend or family member for respite.

If you are reading this and you have not taken a break in the last six months, the right next action is the Alzheimer's Association 24/7 helpline (1-800-272-3900). They will route you.

9. Hospice and the FAST Scale

9.1 The Functional Assessment Staging Tool (FAST), Reisberg

The FAST scale is a 7-stage instrument for staging functional decline in Alzheimer's disease, developed by Barry Reisberg, MD. (Note: FAST is distinct from CDR, the Clinical Dementia Rating scale, and from GDS, the Global Deterioration Scale, also a Reisberg scale. CMS recognizes all three but they score differently.)

9.2 CMS LCD L34567, hospice eligibility for ADRD

Per CMS Local Coverage Determination L34567 (Hospice, Alzheimer's Disease & Related Disorders), a dementia patient meets terminal-status criteria (life expectancy ≤6 months) when both of the following are present:

1. FAST stage ≥7 with all of: inability to ambulate without assistance; inability to dress without assistance; inability to bathe without assistance; urinary and fecal incontinence; no consistently meaningful verbal communication.
2. At least one secondary condition in the past 12 months:
   • Aspiration pneumonia
   • Upper urinary tract infection (pyelonephritis)
   • Septicemia
   • Stage 3 or 4 pressure ulcers
   • Recurrent fever after antibiotics
   • Inability to maintain sufficient fluid/calorie intake, weight loss ≥10% in 6 months OR serum albumin <2.5 g/dL

9.3 What hospice covers

• RN visits, home-health-aide visits, social work, chaplaincy/spiritual care.
• Bereavement counseling for family up to 13 months post-death.
• All medications related to terminal diagnosis.
• Durable medical equipment and oxygen.
• 5-day inpatient respite per benefit period at a Medicare-certified hospice facility or contracted SNF/hospital.

Two 90-day benefit periods, then unlimited 60-day benefit periods, with face-to-face recertification by hospice physician/NP at day 180 and every 60 days thereafter.

9.4 Top NY hospices serving dementia patients

The largest dementia-serving hospices in NY include VNS Health Hospice Care (NYC), Calvary Hospital (Bronx, the only Medicare-certified standalone hospital that is also a hospice in the U.S.), MJHS Hospice and Palliative Care (NYC + Long Island), Hospice Buffalo (Erie), Visiting Nurse Hospice of Rochester, Hospice of the North Country (Plattsburgh), Hospicare (Tompkins/Cortland), and Niagara Hospice (Niagara). Roughly one-quarter of all U.S. hospice admissions have an Alzheimer's/nervous-system primary diagnosis.

9.5 Hospice does not mean stopping all care

The most damaging family-narrative around hospice is "we're giving up." The honest framing: hospice does not mean stopping all medications, comfort medications, including pain management, are intensified. Hospice does mean stopping curative-intent treatments (chemotherapy for a comorbid cancer; aggressive antibiotics for the 4th UTI of the year if the family/MOLST indicates comfort-focus). Hospice can be revoked at any time. And hospice transfers care to the hospice team but does not require the patient to leave home, most NY hospice care is delivered at home or in the long-term-care setting where the patient resides.

Families who elect hospice spend more time with their loved one at home, not less.

10. NY Driving and Cognitive Impairment

NY is not a mandatory physician-reporting state for cognitive impairment.

• Physicians may voluntarily report drivers via DMV form DS-7 (Physician's Reporting Form) or a letter on physician letterhead, addressed to the DMV's Driver Improvement Bureau.
• The DMV may then schedule a re-examination interview; require a road test; require a supplemental written test; require an OT-administered driver rehabilitation evaluation; or suspend the license pending physician certification.
• Family members or others (including police officers, social workers) can also submit a written report concerning a driver's safety to the DMV.
• The 2024 JAMA Network Open study (Hwang et al., doi:10.1001/jamanetworkopen.2024.8236) found mandatory-reporting states (CA, DE, OR, PA, NV, NJ) had higher dementia underdiagnosis rates because patients avoided seeking care, supporting NY's voluntary approach.

You don't have to be the bad guy. Ask the PCP or memory specialist to make a voluntary DMV report. If you're uncomfortable with that, an OT-administered driver evaluation (covered by Medicare under PT/OT benefits when prescribed for a medical reason) is an objective third-party assessment.

Note on Article 19-A: Article 19-A of the Vehicle and Traffic Law governs commercial bus/truck drivers and certain other classifications, it is not the operative statute for personal driver licenses. The operative authority for medical reporting of personal-vehicle drivers is the DMV's medical reporting framework under VTL § 506 and 15 NYCRR Part 9.

11. Pending NY Legislation 2026 Session

Other watch items:

• Memory care facility licensing standards, NY does not have a separate memory care licensure category distinct from Adult Care Facilities (Assisted Living Residences, Enhanced Assisted Living Residences with Special Needs Assisted Living Residence designation). Advocacy is pushing for stricter dementia-specific staff training requirements.
• Mandatory dementia training for nursing home staff, periodically introduced, not yet enacted.

12. Federal Threats 2026–2028

12.1 OBBBA § 71115 / § 71117, MCO and provider tax phase-down

Public Law 119-21 (the One Big Beautiful Bill Act, signed July 4, 2025) phases down the indirect-hold-harmless threshold on Medicaid provider taxes (including managed care organization taxes) in expansion states, including NY:

• Lowers the threshold by 0.5 percentage points each fiscal year, beginning FY 2028, until the threshold reaches 3.5% in FY 2032.
• States with affected MCO taxes have until the end of the state fiscal year ending in calendar year 2026 to comply with the new uniformity/redistributive requirements.
• NY's Medicaid Managed Care MCO tax is among the largest in the country; the phase-down is projected to compress NY federal Medicaid match revenue meaningfully by 2028–2032 unless NY backfills with state revenue.

The LTSS programs that NY dementia families depend on (MLTC, NHTD, institutional Medicaid) are funded via this Medicaid MCO/provider tax architecture. Most of the impact is 2028+; the macro funding dynamics matter for long-term planning.

12.2 OBBBA § 71121, new 1915(c)(11) HCBS waiver authority

OBBBA § 71121 amends 42 USC § 1396n to add a new subsection (c)(11) granting the HHS Secretary authority to approve state HCBS waivers without the institutional level-of-care requirement, effective July 1, 2028. This could enable a dementia-specific waiver in NY (for individuals at MCI/early dementia stage who don't yet meet NF level of care). NY has not announced a § 71121 waiver filing as of May 5, 2026.

12.3 GUIDE Model funding stability

CMS Innovation Center models created during the prior administration are subject to ongoing review. As of May 5, 2026, GUIDE has not been terminated; participating organizations continue under contract through the 8-year model term (through June 30, 2032). The 2025 CMMI announcement of five new models (ACCESS, BALANCE, MAHA ELEVATE, GLOBE, GUARD) without naming GUIDE as continuing has raised concerns, but GUIDE remains operational at NY participants today.

12.4 Medicare AWV + Cognitive Assessment Fee Schedule

The 2027 Medicare Physician Fee Schedule (rule typically released July 2026 / final November 2026) will determine whether AWV cognitive screening and CPT 99483 reimbursement levels keep pace with inflation. CMS in 2024 increased CPT 99483 RVUs significantly to incentivize uptake; 2026 rates remain elevated.

13. Eight Common Myths to Let Go Of

Eight myths a NY dementia family should release before they go down a wrong path.

1. "Some memory loss is just normal aging, Alzheimer's is when it gets bad." Age-associated memory complaints (occasional name retrieval slips) are normal. Alzheimer's disease and other dementias are not normal aging, they are diseases caused by neurodegeneration, and they are diagnosable.

2. "Memory loss equals Alzheimer's." Alzheimer's disease accounts for roughly 60–80% of dementia cases. Other major causes include vascular dementia, Lewy body dementia (DLB), frontotemporal dementia (FTD), Parkinson's disease dementia, mixed pathology dementia, and reversible/treatable mimics, B12 deficiency, hypothyroidism, normal pressure hydrocephalus, depression, medication side effects, urinary tract infection-induced delirium. A real workup at a CEAD or memory center distinguishes these.

3. "There's nothing you can do." Two FDA-approved disease-modifying therapies, lecanemab (Leqembi) and donanemab (Kisunla), are now available in NY for early symptomatic Alzheimer's with confirmed amyloid pathology. Donanemab in TRAILBLAZER-ALZ 2 slowed clinical progression by 22–35% over 18 months. Lecanemab in CLARITY-AD slowed clinical decline 27% over 18 months.

4. "Medicare covers nursing home for dementia." Medicare pays for up to 100 days of post-hospitalization skilled nursing care (the first 20 days at 100%, days 21–100 with a daily coinsurance, $209.50/day in 2025). Medicare does not pay for long-term custodial dementia nursing home care. Medicaid does, after a spend-down.

5. "Hospice means giving up." Hospice is comfort-focused care for individuals with a prognosis of six months or less. Families who elect hospice spend more time with their loved one at home, not less. Hospice does not stop comfort medications; it stops curative-intent treatments.

6. "I have to take their car keys away myself." New York is not a mandatory physician-reporting state. NY physicians may voluntarily report drivers via DMV form DS-7 or a letter on physician letterhead. Families don't have to do this alone.

7. "Family members can be paid through Medicare to care for someone with dementia." Medicare does not pay family caregivers, full stop. The pathway in NY is the Consumer Directed Personal Assistance Program (CDPAP) under Medicaid, which permits adult children, friends, and (post-2016 expansion) certain spouses to be paid by Medicaid for hands-on personal care provided to a relative who is Medicaid-enrolled with a qualifying functional need. See companion How to Get Paid as a Family Caregiver in New York.

8. "Putting Mom in a nursing home is abandonment." The honest framing: home care, with respite layered in, is the right answer for many families until it isn't. Triggers for nursing-home transition are well-documented in the geriatric literature: 24/7 supervision needs the family cannot meet without harming their own health; combative or wandering behavior that creates safety risk; medical complexity (tube feeding, complex wound care, IV antibiotics) that exceeds home-care training; caregiver health collapse. NY's MOLST + Health Care Proxy + Durable POA + 60-month Medicaid spend-down planning + Article 81 guardianship architecture exists precisely because families face this transition. The right care setting is not a moral test, it's a logistics decision.

14. Crisis Lines and Hotlines

Additional Resources

Federal statute and regulation

• 42 USC § 3030s, § 3030s-1 (Older Americans Act NFCSP)
• 42 USC § 1396n (Medicaid HCBS authorities)
• 42 CFR § 418 (Medicare hospice)
• 38 USC § 1720G (VA Caregiver Support Program)
• 38 CFR § 71.40 (PCAFC)
• 90 FR 47891 (PCAFC Legacy Extension Final Rule, 9/29/2025)
• P.L. 119-21 §§ 71115, 71117, 71121 (One Big Beautiful Bill Act)

NY statute and case law

• NY PHL Article 29-C (Health Care Proxy) §§ 2980-2994
• NY PHL Article 29-CC (Family Health Care Decisions Act) §§ 2994-a through 2994-u
• NY GOL §§ 5-1501 through 5-1514 (Power of Attorney)
• NY MHL Article 81 (Guardianship)
• NY Elder Law § 214-d (NY Connects)
• Matter of Mildred M.J., 43 A.D.3d 1391 (4th Dep't 2007)

FDA actions

• Lecanemab (Leqembi) FDA Traditional Approval, July 6, 2023
• Donanemab (Kisunla) FDA Traditional Approval, July 2, 2024
• Brexpiprazole (Rexulti) FDA AD agitation indication, May 10, 2023

CMS / federal program

• CMS LCD L34567 (Hospice, Alzheimer's Disease & Related Disorders)
• CMS GUIDE Model, https://www.cms.gov/priorities/innovation/innovation-models/guide
• CMS Cognitive Assessment & Care Plan Services, https://www.cms.gov/medicare/payment/fee-schedules/physician/cognitive-assessment
• CMS Hospice Monitoring Report April 2025
• NCD 200.3 (Lecanemab/Donanemab coverage)

NYSDOH / NY agency

• NYSDOH Bureau of Healthy Aging, https://www.health.ny.gov/diseases/conditions/dementia/
• NYSDOH CEAD At-A-Glance, https://www.health.ny.gov/diseases/conditions/dementia/docs/cead_at-a-glance.pdf
• NYSDOH ADCSI Single Source Procurement
• NYSDOH MOLST page, https://www.health.ny.gov/professionals/patients/patient_rights/molst/
• NYSDOH NHTD Waiver, https://www.health.ny.gov/facilities/long_term_care/nhtd/
• NYSDOH MLTC Plan Directory, https://www.health.ny.gov/health_care/medicaid/redesign/mrt90/plan_directory/index.htm
• NYRx Medicaid Pharmacy Program PDL (revised April 23, 2026)
• NYSOFA, https://aging.ny.gov/
• NY Connects, https://www.nyconnects.ny.gov
• NY Master Plan for Aging, https://planforaging.ny.gov/
• NY DMV Report a Medical Condition, https://dmv.ny.gov/report-a-medical-condition

Alzheimer's Association

• 2026 Facts and Figures, https://www.alz.org/alzheimers-dementia/facts-figures
• 24/7 Helpline, 1-800-272-3900
• NY chapters: NYC, Long Island, Hudson Valley, Northeastern NY, Central NY, Rochester & Finger Lakes, Western NY
• MedicAlert + Safe Return wandering registry
• Center for Dementia Respite Innovation (CDRI)

Peer-reviewed

• 2026 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia, doi:10.1002/alz.71345
• Hwang Y, et al. "DMV Reporting Mandates of Dementia Diagnoses and Dementia Underdiagnosis." JAMA Network Open. 2024;7(4):e248236
• Schulz R, et al. REACH-II. Ann Intern Med. 2006;145(10):727-738
• Cochrane Review, Validation Therapy for Dementia (Neal & Barton Wright 2003; Scales et al. 2018)
• Cochrane Review, Reminiscence Therapy (Woods et al. 2018)
• Lancet Commission on Dementia Prevention, Intervention, and Care 2024 update

Reputable secondary

• AARP/NAC Caregiving in the US 2025, https://www.aarp.org/pri/topics/ltss/family-caregiving/caregiving-in-the-us-2025/
• NHPCO/Alliance for Care at Home 2024 Facts and Figures
• NYSBA FHCDA Resource Center
• LeadingAge NY GUIDE Models tracker
• Compassion & Choices NY (Medical Aid in Dying)
• End of Life Choices NY

Learn More

• Understanding the Stages of Dementia: What to Expect
• Managing Dementia Behaviors: Agitation, Aggression, and Sundowning
• Communicating With Someone Who Has Dementia
• Daily Care for Someone With Dementia: Bathing, Dressing, and Eating
• Dementia, Wandering, and Home Safety
• Late-Stage and End-of-Life Dementia Care
• New York Caregiver Pillar
• How to Get Paid as a Family Caregiver in New York
• Respite Care in New York
• New York Kinship Caregiver Guide
• New York Caregiver Programs

Find personalized help navigating New York dementia care resources at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.